Yamanouchi Deal Brings MediGene Breathing Space
Executive Summary
MediGene's recent licensing deal with Yamanouchi buys the German biotech time, but does little to strengthen its long-term finances. For this, MediGene will likely have to brave the cold waters of the German capital markets. It will be the first biotech to do so since Germany's growth market collapsed in 2001.
You may also be interested in...
The Pan European Licensing Opportunity
Since 2000, there have been almost four times more product licensing deals signed for North America than for Europe. Granted, Europe is a more complex market, and the US produces a higher proportion of new drugs. But the figures spell a big opportunity for those firms able to offer truly pan-European scope and expertise.
Getting Late Stage Products Early
Thanks to its speedy deal with Zentaris (a subsidiary of Degussa), two-year old discovery-based start up Ardana Bioscience has leaped into the clinic with a phase II product. Now it's planning more late-stage deals, hoping that investors who typically ignore early-stage companies will finance a commercially focused organization with a track record of in-licensing the right drugs.
Senexis Ltd.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.